Successful Treatment of CNS ‐ PTLD Using Systemic and Intrathecal Rituximab and Donor Lymphocyte Infusion | Synapse
April 17, 2026
Successful Treatment of CNS ‐ PTLD Using Systemic and Intrathecal Rituximab and Donor Lymphocyte Infusion
Key Points
This research aims to evaluate the effectiveness of systemic and intrathecal rituximab combined with donor lymphocyte infusion for treating CNS PTLD.
Combined systemic and intrathecal administration of rituximab
Administration of donor lymphocyte infusion
Evaluation of patient outcomes after treatment
Improvement in CNS PTLD symptoms after treatment
Enhanced patient response rates noted
Potential reduction in recurrence observed
Abstract
The authors declare no conflicts of interest. The data that support the findings of this study are available from the corresponding author upon reasonable request.